Eli Lilly Will Sell Zepbound Through Telehealth Company Ro

Eli Lilly Will Sell Zepbound Through Telehealth Company Ro in a Swipe at Legal Copycats
Amid new worries that legal copycats of the weight-loss drugs from Eli Lilly and Novo Nordisk could erode the market for the branded drugs, Lilly on Wednesday said it would sell a version of Zepbound through the telemedicine company Ro.
Eli Lilly taps Ro to help it sell a cheaper version of its weight-loss drug
Eli Lilly is partnering with the Flatiron-based telehealth company Ro to sell a cheaper version of its popular weight-loss drug directly to patients.
Ro partners with Eli Lilly to expand access to Zepbound vials
Eli Lilly (LLY) has added a new telehealth partner to expand access to single-dose vials of its blockbuster weight loss drug Zepbound. Ro Health is joining other telehealth platforms and Amazon Pharmacy (AMZN) in giving patients access to Lilly's top GLP-1 product by plugging in to the pharmaceutical giant's new direct-to-consumer platform,
Lilly to offer single-dose vials of weight-loss drug on telehealth platform Ro
By Sneha S K (Reuters) -Telehealth company Ro said on Wednesday it will offer single-dose vials of Eli Lilly's weight-loss drug Zepbound to patients with obesity, becoming the first alternative platform for the lower-cost version of the drug to Lilly's own website.
Ro to offer lower-price vials of weight loss drug Zepbound by teaming up with Eli Lilly
It is made possible through a first-of-a-kind integration with Eli Lilly's direct-to-consumer website, and aims to streamline access to the popular treatment.
RO WORKS WITH LILLY TO STREAMLINE PATIENT ACCESS TO AUTHENTIC ZEPBOUND® SINGLE-DOSE VIALS BY INTEGRATING WITH LILLY'S PHARMACY CHANNEL
Ro today announced it is working with Eli Lilly and Company to streamline access to Zepbound® (tirzepatide) single-dose vials for Ro patients with obesity. The vials will be available as a treatment option with an on-label prescription from a Ro-affiliated provider via an integration with the LillyDirect® self-pay pharmacy channel.
Telehealth firm Ro to provide single-dose vials of Lilly's Zepbound to obesity patients
Telehealth company Ro said on Wednesday it will provide access to single-dose vials of Eli Lilly's weight-loss drug Zepbound to patients with obesity.
Fierce Healthcare6h
Ro teams up with Eli Lilly to offer single-dose vials of weight loss drug Zepbound
Direct-to-consumer health and wellness company Ro will now offer access to lower-priced, single-dose vials of weight loss ...
STAT23h
Eli Lilly strikes Zepbound deal with Ro, amid questions about future of compounded GLP-1s
Eli Lilly strikes Zepbound deal with the telehealth platform Ro, amid questions about future of compounded GLP-1s.
pharmaphorum17h
Lilly adds another sales channel for obesity drug Zepbound
"Offering Zepbound single-dose vials…through another platform to LillyDirect will help ensure broader availability of ...
Eli Lilly Stock Could Have a Huge Growth Catalyst in Early 2025
Eli Lilly ( LLY -0.44%) may seem like an expensive stock to invest in right now. It's trading at close to 90 times its ...
Ro, Lilly partnership creates volatility for Hims & Hers shares, says Leerink
The partnership between Ro and Eli Lilly (LLY) to streamline access to Lilly’s GLP-1 Zepbound single-dose vials for Ro patients with obesity is ...
STAT1d
Eli Lilly’s new maneuvers in GLP-1 treatment
Want to stay on top of the science and politics driving biotech today? Sign up to get our biotech newsletter in your inbox. Good morning, hope everyone is ...